Journal
RHEUMATOLOGY
Volume 54, Issue 1, Pages 20-28Publisher
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/keu237
Keywords
psoriatic arthritis; tumour necrosis factor inhibitors; disease-modifying anti-rheumatic drug; treatment; review; ustekinumab; apremilast; IL-17 inhibitor; rituximab; methotrexate
Categories
Ask authors/readers for more resources
PsA is a systemic inflammatory condition that affects 20-30% of patients with psoriasis. It is characterized by potential involvement of diverse tissues, including peripheral and axial joints, enthesitis, dactylitis and skin and nail disease. The degree of involvement in each domain can vary over time in individual patients and can differ substantially between PsA patients. The clinical heterogeneity along with the varying extent of severity and activity can pose significant challenges to treatment. Although some studies had suggested immunopathophysiological similarities between PsA and RA, more recently important distinctions have been defined. Similarly, although some immunomodulatory therapies have proved effective for both PsA and RA, recent data suggest distinct responses to certain targeted therapies. Herein, current DMARDs and biologic agents as well as the potential role of emerging therapeutics will be reviewed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available